Match!
Rajat Bansal
Columbia University
ImmunologyT cellWaldenstrom macroglobulinemiaChimeric antigen receptorDiabetes mellitusMedicine
2Publications
1H-index
1Citations
What is this?
Publications 2
Newest
#1Rajat Bansal (Columbia University)H-Index: 1
#2Ran Reshef (Columbia University)H-Index: 24
Abstract Chimeric antigen receptor (CAR) T cell therapy is currently approved for treatment of refractory B-cell malignancies. Response rates in these diseases are impressive by historical standards, but most patients do not have a durable response and there remains room for improvement. To date, CAR T cell activity has been even more limited in solid malignancies. These limitations are thought to be due to several pathways of resistance to CAR T cells, including cell-intrinsic mechanisms and th...
1 CitationsSource
#1Rajat Bansal (Columbia University)H-Index: 1
#2Joseph G. Jurcic (Columbia University)H-Index: 33
Last. Ran Reshef (Columbia University)H-Index: 24
view all 5 authors...
Source
1